💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Hydroquinone

CHEMBL537 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
110.1 g/mol
LogP
0.6
Phase
4

A topical skin-lightening agent used to treat hyperpigmentation conditions such as melasma, age spots, and post-inflammatory hyperpigmentation by inhibiting the enzyme tyrosinase, which is needed for melanin production in the skin. It has also been investigated for antioxidant and other biological properties in research contexts. Long-term or excessive use can paradoxically cause ochronosis, a darkening of the skin.

น้ำหนักโมเลกุล

110.1100 g/mol

LogP

0.60

TPSA

40.50 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Rheumatoid Arthritis Alzheimer's Disease

กลไกการออกฤทธิ์

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Oc1ccc(O)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H

                

                

                

                    
                    

                        
Molecular Formula

                        
C6H6O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
พันธะที่หมุนได้

                        
0

                    

                    
                    
                    

                        
อะตอมหนัก

                        
8

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A topical skin-lightening agent used to treat hyperpigmentation conditions such as melasma, age spots, and post-inflammatory hyperpigmentation by inhibiting the enzyme tyrosinase, which is needed for melanin production in the skin. It has also been investigated for antioxidant and other biological properties in research contexts. Long-term or excessive use can paradoxically cause ochronosis, a darkening of the skin.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Hydroquinone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL537.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 785.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.